A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

BACKGROUND: First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was shown to target kinases involved in immune-escape and to prolong survival in patients pre-treated with tyrosine-kinase-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Procopio, Giuseppe, Claps, Mélanie, Pircher, Chiara, Porcu, Luca, Sepe, Pierangela, Guadalupi, Valentina, De Giorgi, Ugo, Bimbatti, Davide, Nolè, Franco, Carrozza, Francesco, Buti, Sebastiano, Iacovelli, Roberto, Ciccarese, Chiara, Masini, Cristina, Baldessari, Cinzia, Doni, Laura, Cusmai, Antonio, Gernone, Angela, Scagliarini, Sarah, Pignata, Sandro, de Braud, Filippo, Verzoni, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896529/
https://www.ncbi.nlm.nih.gov/pubmed/36447337
http://dx.doi.org/10.1177/03008916221138881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896529/
https://www.ncbi.nlm.nih.gov/pubmed/36447337
http://dx.doi.org/10.1177/03008916221138881

Ejemplares similares